Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study

BMC Cancer

Eiliv Lund¹  Nicolle Mode¹  Marit Waaseth³  Jean-Christophe Thalabard² 

[1] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø - The Arctic University of Norway, Tromsø, Norway

[2] Applied Mathematics Lab, Paris Descartes University, Sorbonne Paris Cité, Assistance Publique- Hôpitaux de Paris, UMR CNRS 8145, Paris, France

[3] Department of Pharmacy, University of Tromsø - The Arctic University of Norway, Tromsø, Norway

关键词: Hormone therapy;    Overdiagnosis;    Mammography screening;    Breast cancer;   

Others  :  859178
DOI  :  10.1186/1471-2407-13-614

 received in 2013-09-13, accepted in 2013-12-06,  发布年份 2013

【 摘 要 】

Background

There is increasing ambiguity towards national mammographic screening programs due to varying publicized estimates of overdiagnosis, i.e., breast cancer that would not have been diagnosed in the women’s lifetime outside screening. This analysis compares the cumulative incidence of breast cancer in screened and unscreened women in Norway from the start of the fully implemented Norwegian Breast Cancer Screening Program (NBCSP) in 2005.

Methods

Subjects were 53 363 women in the Norwegian Women and Cancer (NOWAC) study, aged 52–79 years, with follow-up through 2010. Mammogram and breast cancer risk factor information were taken from the most recent questionnaire (2002–07) before the start of individual follow-up. The analysis differentiated screening into incidence (52–69 years) and post screening (70–79 years). Relative risks (RR) were estimated by Poisson regression.

Results

The analysis failed to detect a significantly increased cumulative incidence rate in screened versus other women 52–79 years. RR of breast cancer among women outside the NBCSP, the “control group”, was non-significantly reduced by 7% (RR = 0∙93; 95% confidence interval 0∙79 to 1∙10) compared to those in the program. The RR was attenuated when adjusted for risk factors; RR_adj = 0∙97 (0∙82 to 1∙15). The control group consisted of two subpopulations, those who only had a mammogram outside the program (RR_adj =1∙04; 0∙86 to 1∙26) and those who never had a mammogram (RR_adj = 0∙77; 0∙59 to 1∙01). These groups differed significantly with respect to risk factors for breast cancer, partly as a consequence of the prescription rules for hormone therapy which indicate a mammogram.

Conclusions

In the fully implemented NBCSP, no significant difference was found in cumulative incidence rates of breast cancer between NOWAC women screened and not screened. Naïve comparisons of screened and unscreened women may be affected by important differences in risk factors. The current challenge for the screening program is to improve the diagnostics used at prevalence screenings (ages 50–51).

【 授权许可】

   
2013 Lund et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M, Independent UKPBCS: The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380(9855):1778-1786.
• [2]Falk RS, Hofvind S, Skaane P, Haldorsen T: Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer 2013, 133:705-713.
• [3]Kalager M, Adami HO, Bretthauer M, Tamimi RM: Overdiagnosis of invasive breast cancer due to mammography screening: results from the norwegian screening program. Ann Intern Med 2012, 156(7):491-U461.
• [4]Yen AMF, Duffy SW, Chen THH, Chen LS, Chiu SYH, Fann JCY, Wu WYY, Su CW, Smith RA, Tabar L: Long-term incidence of breast cancer by trial arm in one county of the Swedish Two-County Trial of mammographic screening. Cancer 2012, 118(23):5728-5732.
• [5]Vannier MW: Screening mammography: what good is it and how can we know if It works? J Natl Cancer Inst 2012, 104(14):1039-1040.
• [6]Gotzsche PC, Nielsen M: Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011, (1):CD001877.
• [7]Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B: Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control 2010, 21(2):275-282.
• [8]Jorgensen KJ, Gotzsche PC: Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. Br Med J 2009, 339:b2587.
• [9]Zahl PH, Maehlen J, Welch G: The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008, 168(21):2311-2316.
• [10]Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L: Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol 2007, 8(12):1129-1138.
• [11]Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP: Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. Br Med J 2006, 332(7543):689-691.
• [12]Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J: Overdiagnosis and overtreatment of breast cancer - Estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 2005, 7(6):258-265. BioMed Central Full Text
• [13]Zahl PH, Strand H, Maehlen J: Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. Br Med J 2004, 328(7445):921-924.
• [14]Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E, Grp EW: Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012, 19:42-56.
• [15]Greenland S, Morgenstern H: Ecological bias, confounding, and effect modification. Int J Epidemiol 1989, 18(1):269-274.
• [16]Norsk legemiddelhåndbok [Norwegian Medicine Handbook, In Norwegian] http://legemiddelhandboka.no/ webcite
• [17]Physicans Desk Reference [Felleskatalogen, In Norwegian] http://www.felleskatalogen.no/medisin/ webcite
• [18]Banks E, Beral V, Bull D, Reeves G, Austoker J, English R, Patnick J, Peto R, Vessey M, Wallis M, et al.: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362(9382):419-427.
• [19]Bakken L, Alsaker E, Eggen AE, Lund E: Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 2004, 112(1):130-134.
• [20]Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, Geller BM, Abraham LA, Taplin SH, Dignan M, et al.: Individual and combined effects of age, breast density, and hormone replacement therapy Use on the accuracy of screening mammography. Ann Intern Med 2003, 138(3):168-175.
• [21]Njor SH, Olsen AH, Blichert-Toft M, Schwartz W, Vejborg I, Lynge E: Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ 2013, 346:f1064.
• [22]Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E: An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer 2009, 45(18):3166-3171.
• [23]Cancer Registry of Norway: Cancer in Norway 2009: Cancer incidence, mortality, survival and prevalence in Norway. Oslo, Norway: Cancer Registry of Norway; 2011.
• [24]Hofvind S, Geller B, Vacek P, Thoresen S, Skaane P: Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007, 22(7):447-455.
• [25]Lund E, Dumeaux V, Braaten T, Hjartaker A, Engeset D, Skeie G, Kumle M: Cohort profile: The Norwegian women and cancer study - NOWAC - Kvinner og kreft. Int J Epidemiol 2008, 37(1):36-41.
• [26]Cancer Registry of Norway: Cancer in Norway 2010: Cancer incidence, mortality, survival and prevalence in Norway. Oslo, Norway: Cancer Registry of Norway; 2012.
• [27]Ulm K: A simple method to calculate the confidence-interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990, 131(2):373-375.
• [28]Boniol M, Heanue M: Chapter 7: age-standardisation and denominators. In Cancer Incidence in Five Countinents. IX edition. Edited by Curado MP, Edwards B, Shin HR, Storm J, Ferlay M, Heanue M, Boyle P. Lyon France: International Agency for Research on Cancer; 2007.
• [29]Zou G: A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159(7):702-706.
• [30]International Agency for Research on Cancer: Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 91. Geneva, Switzerland: World Health Organization; 2007.
• [31]National action plan with guidelines for diagnosis, treatment and follow-up of patients with breast cancer [In Norwegian] http://www.helsebiblioteket.no/retningslinjer/brystkreft/2-forebygging/2.2-oppf%C3%B8lging-av-kvinner webcite